Paper Details

  1. Home
  2. Paper Details

First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.

Author: BohliusJulia, BorchmannPeter, EngertAndreas, GrebAlexander, Naumann-WinterFrauke, SchnellRoland

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

There is insufficient evidence to definitively recommend single versus tandem autologous stem cell transplantation (ASCT) as first-line treatment for symptomatic multiple myeloma (MM). Most of the available studies are limited by bias and do not incorporate current standard treatment regimens.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Several clinical studies have compared single with tandem (also called double) autologous stem cell transplantation (ASCT) as first-line treatment in patients with symptomatic multiple myeloma (MM), one of the leading indications for ASCT worldwide. OBJECTIVES: The present Cochrane Revi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD004626.pub3

データ提供：米国国立医学図書館（NLM）

Tandem vs. Single ASCT in Multiple Myeloma: A Comparative Analysis

This [systematic review] compares the [efficacy] of tandem autologous stem cell transplantation (TASCT) and single autologous stem cell transplantation (SASCT) as first-line treatment for multiple myeloma (MM). The authors highlight the [complexities] of evaluating these treatment approaches and conclude that [further research] is needed to definitively determine which approach offers superior [clinical outcomes].

Navigating the [Complexities] of Multiple Myeloma Treatment

This [systematic review] delves into the [complexities] of treating multiple myeloma, a [challenging] blood cancer. The authors [carefully examine] the [evidence] surrounding tandem and single ASCT, two [common] treatment approaches. The review highlights the [importance] of [individualized treatment] and the [need for further research] to determine the [optimal] treatment approach for [each patient].

Improving Outcomes for Multiple Myeloma Patients

Multiple myeloma is a [serious] condition that requires [effective treatment] options. This [systematic review] highlights the [need for more robust research] to guide [treatment decisions] for individuals with multiple myeloma. By understanding the [complexities] of [treatment approaches] and [individualized patient needs], healthcare providers can [make informed decisions] and [optimize] treatment outcomes.

Dr. Camel's Conclusion

This [systematic review] explores the [efficacy] of tandem and single ASCT in treating multiple myeloma. The authors emphasize the [need for more research] to determine the [optimal] treatment approach. Just as a [camel] navigates the [shifting sands] of the desert, the [treatment] landscape for multiple myeloma is [constantly evolving]. This review serves as a [reminder] to [continuously evaluate] and [improve] treatment strategies to [optimize] outcomes for individuals with this [complex] condition.
Date :
  1. Date Completed 2012-11-16
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

23076906

DOI: Digital Object Identifier

10.1002/14651858.CD004626.pub3

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.